Sargramostim inhalation - Nobel Pharma
Alternative Names: Sargramostim-inhalation; sargramostiminhalationLatest Information Update: 16 Oct 2023
At a glance
- Originator Nobelpharma
- Class Adjuvants; Anti-infectives; Antidementias; Antineoplastics; Antiparkinsonians; Antivirals; Chemoprotectants; Granulocyte-macrophage colony-stimulating factors; Radioprotectives; Recombinant proteins
- Mechanism of Action Granulocyte colony stimulating factor stimulants; Granulocyte stimulants; Haematopoiesis stimulants; Macrophage stimulants; Neutrophil stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II/III COVID-19 respiratory infection
Most Recent Events
- 16 Oct 2023 Sargramostim is still in phase II/III trial for COVID-19 respiratory infection (Adjunctive treatment) in Japan (Inhalation) (NCT04642950)
- 17 Dec 2020 Phase-II/III clinical trials in COVID-19 respiratory infection (Adjunctive treatment) in Japan (Inhalation)
- 24 Nov 2020 Preclinical trials in COVID-19 respiratory infection in Japan (Inhalation)